Despite its potent anti-tumor and pro-inflammatory attributes and some promising signs of activity in certain tumor indications, the clinical utility of recombinant IFNα has been limited due to a narrow therapeutic index, driven by significant IFNα-related toxicities including nausea, severe flu-like symptoms, vasculopathic complications (e.g., thrombocytopenia and leukopenia), and negative impacts on the nervous system, resulting in depression and anxiety [2–5]. Here, IFNA2 is linked to major depressive disorder.